Company profile
CytoDyn Inc.
OTC: CYDY · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 15GM —SS 59
v0.1 · 25/100 weight · pillars only
↑ return on assets, listing tenure · ↓ revenue growth (YoY), disclosure history
Methodology →Revenue TTM
-$5.9M
Rev growth YoY (TTM)
-11932.0%
Net income (FY)
$3.7M
Employees
13
as of 2026-08-12
Market cap
$260.2M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02023
Net income$3.7M$3.7M2025
Operating income$9.7M$9.7M2025
Total assets$18.0M$18.0M2025
Liabilities$114.1M$114.1M2025
Equity-$96.0M-$96.0M2025
Revenue trend
FY2022 – FY2023 · USD
FY22
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is CytoDyn Inc.’s revenue?
CytoDyn Inc. booked $0 in FY2023 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a Infinity% net margin.
Peers · Healthcare
Eledon Pharmaceuticals, Inc.39DFulcrum Therapeutics, Inc.59CALX Oncology Holdings Inc.37DCapricor Therapeutics, Inc.57CMinerva Neurosciences, Inc.38DEupraxia Pharmaceuticals Inc.42DNeighbors
Clark →Key facts
CEOJacob Lalezari
SectorHealthcare
IndustryBiotechnology
HeadquartersVancouver, WA
ExchangeOTC: CYDY
Employees13
IPO date2006-12-13
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.